Aggressive NK-cell Leukemia

MONDO:0019470 Pathograph 9 mature T-cell and NK-cell non-Hodgkin lymphoma chronic leukemia

Aggressive NK-cell leukemia is a rare, fulminant mature NK-cell hematologic malignancy. It commonly presents as an acute systemic inflammatory and leukemic illness with fever, constitutional symptoms, hepatosplenomegaly, coagulopathy, hemophagocytic syndrome or HLH-like disease, and rapid multiorgan complications. Most cases are Epstein-Barr virus-associated, but EBV-negative cases are recognized. Molecular evidence supports recurrent JAK-STAT activation, TP53/DNA-repair impairment, epigenetic dysregulation, and additional RAS-MAPK/DDX3X lesions. Treatment usually requires urgent asparaginase/pegaspargase-containing chemotherapy with consideration of allogeneic hematopoietic stem cell transplantation in responding eligible patients, but outcomes remain poor.

Ask OpenScientist

Ask a research question about Aggressive NK-cell Leukemia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
1
Histopath.
5
Phenotypes
9
Pathograph
5
Genes
3
Treatments
2
Subtypes
2
Differentials
3
Trials
10
References
1
Deep Research
◆

Subtypes

2
Classic ANKL
Fulminant ANKL without a prolonged infectious mononucleosis-like prodrome. In the Tang multicenter cohort, classic ANKL had shorter survival and enrichment for TP53 mutation relative to the subacute subtype.
Show evidence (1 reference)
PMID:29263371 SUPPORT Human Clinical
"All these data suggested that patients with prolonged prodromal phases, whom we define here as “subacute ANKL”, may represent a clinical subtype of ANKL which differed from the others, whom we define here as “classic ANKL”."
The multicenter cohort explicitly distinguishes classic ANKL from the subacute clinical subtype.
Subacute ANKL
15.93%
ANKL with a prolonged infectious mononucleosis-like prodrome before the fulminant phase. This subtype was associated with better survival and lower TP53 mutation frequency than classic ANKL in the Tang cohort.
Show evidence (2 references)
PMID:29263371 SUPPORT Human Clinical
"Intriguingly, a subacute clinical course was demonstrated in 18 ANKL patients (15.93%, 18/113)."
The multicenter cohort quantified the subacute subtype frequency.
PMID:29263371 SUPPORT Human Clinical
"They manifested infectious mononucleosis (IM)-like symptoms (including fever, lymphocytosis or mononucleosis, lymphadenopathy, and hepatosplenomegaly) for more than 90 days (median: 115 days, range: 90–450 days), prior to the fulminant onset (Table 1)."
This defines the subacute ANKL prodromal clinical course.
⚙

Pathophysiology

6
EBV-Associated NK-Cell Transformation
EBV-associated ANKL arises in the mature NK-cell lineage and can present as EBV-HLH before the malignant NK-cell population is recognized. EBV positivity should be interpreted with morphology and immunophenotyping because EBV-HLH without neoplasia can clinically overlap.
natural killer cell link
cytokine-mediated signaling pathway link ↑ INCREASED
bone marrow link blood link
Downstream
Malignant NK-Cell Expansion EBV-associated NK-lineage transformation precedes systemic malignant NK-cell expansion.
Show evidence (1 reference)
DOI:10.3389/frhem.2024.1413794 SUPPORT Human Clinical
"Here we present a case of ANKL in a patient presenting with EBV-HLH."
This supports EBV-HLH as a clinically important presentation context for ANKL and anchors EBV-associated transformation in a human patient.
Malignant NK-Cell Expansion
The neoplastic cells retain NK-lineage markers, particularly CD56 and CD94, while lacking surface T-cell markers such as surface CD3, CD5, and CD57. Expansion in marrow and blood produces the leukemic presentation and drives tissue involvement in hematopoietic and reticuloendothelial organs.
natural killer cell link
cell population proliferation link ↑ INCREASED
bone marrow link blood link liver link spleen link
Downstream
JAK-STAT Pathway Activation Expanded malignant NK cells can harbor JAK-STAT lesions that promote growth and survival.
TP53 and DNA-Repair Impairment Expanded malignant NK cells can acquire TP53 and DNA-repair lesions.
Epigenetic Modifier Dysregulation Expanded malignant NK cells can harbor recurrent epigenetic-modifier lesions.
HLH-Like Systemic Inflammation and Coagulopathy Malignant NK-cell disease can trigger fulminant inflammatory and coagulation complications.
Show evidence (1 reference)
DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical
"The neoplastic cells were positive for CD56 and CD94, and negative for surface CD3, CD5, and CD57 in all cases assessed."
This 12-case clinicopathologic series supports NK-lineage malignant-cell expansion with the characteristic diagnostic immunophenotype.
JAK-STAT Pathway Activation
JAK-STAT pathway activation is a major recurrent molecular abnormality in ANKL. STAT3 mutation and additional JAK-STAT copy-gain or phosphatase lesions provide a growth and survival mechanism and a rationale for pathway-directed drug profiling.
natural killer cell link
cell surface receptor signaling pathway via JAK-STAT link ↑ INCREASED
Downstream
Malignant NK-Cell Expansion JAK-STAT activation sustains proliferation and survival of malignant NK cells.
Show evidence (2 references)
DOI:10.3390/cancers12102900 SUPPORT Other
"Molecular abnormalities that occur in ANKL can be divided into three major groups: JAK/STAT pathway activation, epigenetic dysregulation, and impairment of TP53 and DNA repair."
The review identifies JAK/STAT pathway activation as a major molecular abnormality in ANKL.
DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical
"We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as inDDX3X(29%) and epigenetic modifiers (50%)."
This human tumor genomic study supports recurrent STAT3 mutation in ANKL.
TP53 and DNA-Repair Impairment
TP53 mutation, abnormal p53 expression, and broader DNA-repair impairment form a distinct pathophysiologic axis in ANKL. These alterations are most directly linked to loss of cell-cycle checkpoint and apoptosis control.
natural killer cell link
regulation of apoptotic process link ⚠ ABNORMAL
Downstream
Malignant NK-Cell Expansion TP53 and DNA-repair impairment can permit survival and expansion of genomically abnormal NK cells.
Show evidence (2 references)
DOI:10.3390/cancers12102900 SUPPORT Other
"Molecular abnormalities that occur in ANKL can be divided into three major groups: JAK/STAT pathway activation, epigenetic dysregulation, and impairment of TP53 and DNA repair."
The review separates TP53 and DNA-repair impairment from JAK-STAT and epigenetic mechanisms.
DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical
"TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2 mutations were each detected in 2 of 6 cases."
This clinicopathologic series supports recurrent TP53 mutation in ANKL.
Epigenetic Modifier Dysregulation
Epigenetic dysregulation is a distinct recurrent molecular class in ANKL, including mutations in epigenetic regulatory genes such as ASXL1 and TET2 and broader epigenetic-modifier alterations in sequencing cohorts.
natural killer cell link
Downstream
Malignant NK-Cell Expansion Epigenetic dysregulation can alter malignant NK-cell transcriptional control and survival.
Show evidence (2 references)
DOI:10.3390/cancers12102900 SUPPORT Other
"Molecular abnormalities that occur in ANKL can be divided into three major groups: JAK/STAT pathway activation, epigenetic dysregulation, and impairment of TP53 and DNA repair."
The review identifies epigenetic dysregulation as an independent major molecular abnormality class in ANKL.
DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical
"We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as inDDX3X(29%) and epigenetic modifiers (50%)."
Whole-exome sequencing supports frequent epigenetic-modifier mutation in ANKL tumors.
HLH-Like Systemic Inflammation and Coagulopathy
ANKL often manifests as a severe systemic inflammatory syndrome with fever, hemophagocytic syndrome or HLH, hepatosplenomegaly, and disseminated intravascular coagulation. These complications contribute to early organ failure and mortality.
natural killer cell link
cytokine-mediated signaling pathway link ↑ INCREASED coagulation link ⚠ ABNORMAL
blood link liver link spleen link
Show evidence (1 reference)
DOI:10.3390/cancers12102900 SUPPORT Other
"Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome."
This review directly links the acute ANKL presentation to fever, hepatosplenomegaly, DIC, and hemophagocytic syndrome.
✶

Histopathology

1
Interstitial and Sinusoidal Bone Marrow Involvement
Bone marrow involvement by ANKL can show interstitial or sinusoidal infiltration patterns, supporting a marrow-based leukemic presentation when interpreted with NK-cell immunophenotyping.
Show evidence (1 reference)
DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical
"Two distinct patterns of bone marrow involvement were identified: interstitial and sinusoidal."
This clinicopathologic series supports the marrow infiltration patterns as a histopathologic feature of ANKL.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Aggressive NK-cell Leukemia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Blood 2
Disseminated Intravascular Coagulation Disseminated intravascular coagulation (HP:0005521)
Show evidence (1 reference)
DOI:10.3390/cancers12102900 SUPPORT Other
"Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome."
The abstract directly supports DIC as a feature of the acute ANKL presentation.
Pancytopenia Pancytopenia (HP:0001876)
Show evidence (1 reference)
DOI:10.1155/crh/7796972 SUPPORT Human Clinical
"We present a case of a 71‐year‐old Caucasian male who developed fever, altered mental status, hepatosplenomegaly, pancytopenia, and hemophagocytic lymphohistiocytosis (HLH) and who was ultimately diagnosed with ANKL."
The case report directly supports pancytopenia as part of an ANKL presentation.
Cardiovascular 1
Hepatosplenomegaly Hepatosplenomegaly (HP:0001433)
Show evidence (1 reference)
DOI:10.3390/cancers12102900 SUPPORT Other
"Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome."
The review abstract directly names hepatosplenomegaly as a common ANKL presentation feature.
Metabolism 1
Fever and Constitutional Symptoms Fever (HP:0001945)
Show evidence (1 reference)
DOI:10.3390/cancers12102900 SUPPORT Other
"Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome."
The abstract explicitly includes fever and constitutional symptoms in the common acute presentation.
Other 1
HLH-Like Hemophagocytic Syndrome Hemophagocytosis (HP:0012156)
Show evidence (2 references)
DOI:10.3389/frhem.2024.1413794 SUPPORT Human Clinical
"Aggressive natural killer cell leukemia (ANKL) is a rare, aggressive hematologic malignancy which often presents as fulminant Epstein-Barr virus (EBV)- driven hemophagocytic lymphohistiocytosis (HLH)."
The case report directly supports EBV-HLH as a frequent and clinically important presentation mode for ANKL.
DOI:10.24953/turkjpediatr.2024.5072 SUPPORT Human Clinical
"HLH can serve as the initial manifestation of ANKL."
The pediatric case series and literature review supports HLH as an initial manifestation.
🧬

Genetic Associations

5
STAT3 (Recurrent somatic mutation and JAK-STAT pathway activation in ANKL)
Show evidence (1 reference)
DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical
"We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as inDDX3X(29%) and epigenetic modifiers (50%)."
Whole-exome sequencing of human ANKL tumors identified recurrent STAT3 mutations.
TP53 (Recurrent TP53 alteration and p53 overexpression in ANKL)
Show evidence (1 reference)
DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical
"TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2 mutations were each detected in 2 of 6 cases."
This clinicopathologic series supports recurrent TP53 mutations in ANKL.
DDX3X (Recurrent somatic mutation in ANKL genomic profiling)
Show evidence (1 reference)
DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical
"We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as inDDX3X(29%) and epigenetic modifiers (50%)."
Whole-exome sequencing of ANKL identified recurrent DDX3X mutation.
ASXL1 (Epigenetic modifier mutation in ANKL)
Show evidence (1 reference)
DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical
"TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2 mutations were each detected in 2 of 6 cases."
This clinicopathologic series supports ASXL1 mutation as a recurrent epigenetic modifier lesion in ANKL.
TET2 (Epigenetic modifier mutation in ANKL)
Show evidence (1 reference)
DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical
"TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2 mutations were each detected in 2 of 6 cases."
This clinicopathologic series supports TET2 mutation as a recurrent epigenetic modifier lesion in ANKL.
💊

Treatments

3
Asparaginase- or Pegaspargase-Containing Chemotherapy
Action: chemotherapy MAXO:0000647
Agent: Pegaspargase ↗
Asparaginase-based regimens, including pegaspargase-containing intensive combinations and modified SMILE-like approaches, are commonly considered for rapid induction. Evidence remains limited because ANKL is rare and outcomes are poor even when responses occur.
Mechanism Target:
INHIBITS Malignant NK-Cell Expansion — Cytotoxic induction chemotherapy attempts to reduce the malignant NK-cell burden.
Show evidence (2 references)
DOI:10.24953/turkjpediatr.2024.5072 PARTIAL Human Clinical
"Intensive combination chemotherapy based on pegaspargase and anthracyclines may be considered for ANKL."
The pediatric case series and literature review supports pegaspargase- based chemotherapy as a considered treatment while preserving uncertainty in the wording.
clinicaltrials:NCT03719105 SUPPORT Human Clinical
"Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia"
The active trial summary supports a modified SMILE pegaspargase-containing regimen for advanced NK lymphoma/leukemia.
Allogeneic Hematopoietic Stem Cell Transplantation
Action: hematopoietic stem cell transplantation MAXO:0000747
Allogeneic hematopoietic stem cell transplantation is considered as consolidation for eligible patients who achieve disease response after induction therapy.
Mechanism Target:
INHIBITS Malignant NK-Cell Expansion — Transplantation aims to consolidate remission after cytoreduction of the malignant NK-cell clone.
Show evidence (2 references)
DOI:10.24953/turkjpediatr.2024.5072 PARTIAL Human Clinical
"Case-2 underwent hematopoietic stem cell transplantation and is currently alive and disease-free."
This human case series supports HSCT as a potential consolidation strategy, but the single-case nature warrants partial support.
clinicaltrials:NCT03719105 SUPPORT Human Clinical
"Both groups proceed to allogeneic stem cell transplant with disease response."
The trial summary supports HSCT consolidation after disease response.
JAK and BCL2 Inhibition
Action: Pharmacotherapy NCIT:C15986
JAK inhibitors and BCL2 inhibitors are emerging rational therapies rather than established ANKL standards. Their rationale comes from ANKL genomic and drug sensitivity profiling showing JAK-STAT pathway involvement and NK-cell sensitivity to JAK and BCL2 inhibition.
Mechanism Target:
INHIBITS JAK-STAT Pathway Activation — JAK inhibition targets recurrent JAK-STAT signaling activity in NK-cell malignancies.
Show evidence (1 reference)
DOI:10.1038/s41467-018-03987-2 PARTIAL In Vitro
"Drug sensitivity profiling further demonstrates the role of the JAK-STAT pathway in the pathogenesis of NK-cell malignancies, identifying NK cells to be highly sensitive to JAK and BCL2 inhibition compared to other hematopoietic cell lineages."
This ex vivo/in vitro drug profiling supports a targeted-therapy rationale, but not an established clinical standard for ANKL.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Aggressive NK-cell Leukemia:

EBV-Driven Hemophagocytic Lymphohistiocytosis Without Neoplasia
Overlapping Features EBV-HLH can be the initial presentation of ANKL, but EBV-HLH without a malignant NK/T-cell population is a key differential diagnosis during early evaluation.
Distinguishing Features
  • Detection of an atypical CD3-/CD56+ NK-cell population in marrow or blood supports ANKL rather than isolated EBV-HLH.
Show evidence (1 reference)
DOI:10.3389/frhem.2024.1413794 SUPPORT Human Clinical
"This case highlights the diagnostic challenges of ANKL given the lack of standardized diagnostic criteria, the importance of considering T/NK cell malignancies in the differential diagnosis of EBV-HLH, and adds to the literature on this rare disease."
This case report explicitly states that T/NK malignancies must be considered in the differential diagnosis of EBV-HLH.
Extranodal NK/T-Cell Lymphoma
Overlapping Features Extranodal NK/T-cell lymphoma is another EBV-associated NK/T malignancy with overlapping immunophenotypic and clinical features, especially when disseminated. Leukemic blood and marrow involvement support ANKL.
Distinguishing Features
  • Primary extranodal mass-forming disease favors extranodal NK/T-cell lymphoma; systemic leukemic marrow and blood involvement favors ANKL.
Show evidence (1 reference)
DOI:10.3390/cancers12102900 SUPPORT Other
"This acute clinical presentation and the variable pathologic and immunophenotypic features of ANKL overlap with other diagnostic entities, making it challenging to establish a timely and accurate diagnosis of ANKL."
The review supports clinically important diagnostic overlap with other NK/T-cell entities.
🔬

Clinical Trials

3
NCT03719105
Pilot chemoimmunotherapy study using modified SMILE-style induction for advanced NK lymphoma/leukemia followed by allogeneic stem cell transplant for responders.
Show evidence (1 reference)
clinicaltrials:NCT03719105 SUPPORT Human Clinical
"Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia"
The trial summary directly describes the ANKL-relevant induction regimen for advanced NK lymphoma/leukemia.
NCT03623087
SIMPLE chemotherapy study for NK/T-cell malignancies, derived from a PIGLETS chemotherapy protocol used in extranodal NK/T-cell lymphoma and aggressive NK leukemia.
Show evidence (1 reference)
clinicaltrials:NCT03623087 SUPPORT Human Clinical
"NK malignancies consist of two different clinical entities, extranodal NK/T cell lymphoma and aggressive NK leukaemia."
The trial summary explicitly includes aggressive NK leukemia in the NK malignancy population targeted by the chemotherapy study.
NCT05863234
Phase I/II dose-escalation clinical trial evaluating repeated continuous intravenous PPMX-T003 in aggressive NK-cell leukemia.
Show evidence (1 reference)
clinicaltrials:NCT05863234 SUPPORT Human Clinical
"This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia."
The trial summary directly supports an ANKL-specific PPMX-T003 clinical trial.
{ }

Source YAML

click to show 
name: Aggressive NK-cell Leukemia
creation_date: "2026-05-11T17:49:12Z"
updated_date: "2026-05-11T18:54:27Z"
description: >-
  Aggressive NK-cell leukemia is a rare, fulminant mature NK-cell hematologic
  malignancy. It commonly presents as an acute systemic inflammatory and
  leukemic illness with fever, constitutional symptoms, hepatosplenomegaly,
  coagulopathy, hemophagocytic syndrome or HLH-like disease, and rapid
  multiorgan complications. Most cases are Epstein-Barr virus-associated, but
  EBV-negative cases are recognized. Molecular evidence supports recurrent
  JAK-STAT activation, TP53/DNA-repair impairment, epigenetic dysregulation,
  and additional RAS-MAPK/DDX3X lesions. Treatment usually requires urgent
  asparaginase/pegaspargase-containing chemotherapy with consideration of
  allogeneic hematopoietic stem cell transplantation in responding eligible
  patients, but outcomes remain poor.
categories:
- Hematologic Malignancy
- Mature NK-Cell Neoplasm
- EBV-Associated Neoplasm
- Rare Cancer
synonyms:
- ANKL
- aggressive NK-cell leukemia/lymphoma
- aggressive natural killer cell leukemia
- NK-cell large granular lymphocyte leukemia
disease_term:
  preferred_term: aggressive NK-cell leukemia
  term:
    id: MONDO:0019470
    label: aggressive NK-cell leukemia
parents:
- mature T-cell and NK-cell non-Hodgkin lymphoma
- chronic leukemia
has_subtypes:
- name: Classic ANKL
  classification: clinical_course
  description: >-
    Fulminant ANKL without a prolonged infectious mononucleosis-like prodrome.
    In the Tang multicenter cohort, classic ANKL had shorter survival and
    enrichment for TP53 mutation relative to the subacute subtype.
  evidence:
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All these data suggested that patients with prolonged prodromal phases,
      whom we define here as “subacute ANKL”, may represent a clinical subtype
      of ANKL which differed from the others, whom we define here as “classic
      ANKL”.
    explanation: >-
      The multicenter cohort explicitly distinguishes classic ANKL from the
      subacute clinical subtype.
- name: Subacute ANKL
  classification: clinical_course
  subtype_frequency: 15.93%
  description: >-
    ANKL with a prolonged infectious mononucleosis-like prodrome before the
    fulminant phase. This subtype was associated with better survival and lower
    TP53 mutation frequency than classic ANKL in the Tang cohort.
  evidence:
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intriguingly, a subacute clinical course was demonstrated in 18 ANKL
      patients (15.93%, 18/113).
    explanation: >-
      The multicenter cohort quantified the subacute subtype frequency.
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They manifested infectious mononucleosis (IM)-like symptoms (including
      fever, lymphocytosis or mononucleosis, lymphadenopathy, and
      hepatosplenomegaly) for more than 90 days (median: 115 days, range:
      90–450 days), prior to the fulminant onset (Table 1).
    explanation: >-
      This defines the subacute ANKL prodromal clinical course.
infectious_agent:
- name: Epstein-Barr Virus
  infectious_agent_term:
    preferred_term: Epstein-Barr virus
    term:
      id: NCBITaxon:10376
      label: human gammaherpesvirus 4
  description: >-
    EBV is the central infectious association in aggressive NK-cell leukemia.
    Tumor or marrow EBER positivity supports EBV-associated ANKL, while
    EBV-HLH is an important overlapping presentation and differential context.
  evidence:
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aggressive natural killer cell leukemia (ANKL) is a rare, aggressive
      hematologic malignancy which often presents as fulminant Epstein-Barr
      virus (EBV)- driven hemophagocytic lymphohistiocytosis (HLH).
    explanation: >-
      This human case report explicitly frames ANKL as an EBV-driven HLH-like
      malignancy presentation.
pathophysiology:
- name: EBV-Associated NK-Cell Transformation
  description: >-
    EBV-associated ANKL arises in the mature NK-cell lineage and can present as
    EBV-HLH before the malignant NK-cell population is recognized. EBV positivity
    should be interpreted with morphology and immunophenotyping because EBV-HLH
    without neoplasia can clinically overlap.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  - preferred_term: blood
    term:
      id: UBERON:0000178
      label: blood
  biological_processes:
  - preferred_term: cytokine-mediated signaling pathway
    modifier: INCREASED
    term:
      id: GO:0019221
      label: cytokine-mediated signaling pathway
  evidence:
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we present a case of ANKL in a patient presenting with EBV-HLH.
    explanation: >-
      This supports EBV-HLH as a clinically important presentation context for
      ANKL and anchors EBV-associated transformation in a human patient.
  downstream:
  - target: Malignant NK-Cell Expansion
    description: EBV-associated NK-lineage transformation precedes systemic malignant NK-cell expansion.
- name: Malignant NK-Cell Expansion
  description: >-
    The neoplastic cells retain NK-lineage markers, particularly CD56 and CD94,
    while lacking surface T-cell markers such as surface CD3, CD5, and CD57.
    Expansion in marrow and blood produces the leukemic presentation and drives
    tissue involvement in hematopoietic and reticuloendothelial organs.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  - preferred_term: blood
    term:
      id: UBERON:0000178
      label: blood
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  - preferred_term: spleen
    term:
      id: UBERON:0002106
      label: spleen
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The neoplastic cells were positive for CD56 and CD94, and negative for
      surface CD3, CD5, and CD57 in all cases assessed.
    explanation: >-
      This 12-case clinicopathologic series supports NK-lineage malignant-cell
      expansion with the characteristic diagnostic immunophenotype.
  downstream:
  - target: JAK-STAT Pathway Activation
    description: Expanded malignant NK cells can harbor JAK-STAT lesions that promote growth and survival.
  - target: TP53 and DNA-Repair Impairment
    description: Expanded malignant NK cells can acquire TP53 and DNA-repair lesions.
  - target: Epigenetic Modifier Dysregulation
    description: Expanded malignant NK cells can harbor recurrent epigenetic-modifier lesions.
  - target: HLH-Like Systemic Inflammation and Coagulopathy
    description: Malignant NK-cell disease can trigger fulminant inflammatory and coagulation complications.
- name: JAK-STAT Pathway Activation
  description: >-
    JAK-STAT pathway activation is a major recurrent molecular abnormality in
    ANKL. STAT3 mutation and additional JAK-STAT copy-gain or phosphatase
    lesions provide a growth and survival mechanism and a rationale for
    pathway-directed drug profiling.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  biological_processes:
  - preferred_term: cell surface receptor signaling pathway via JAK-STAT
    modifier: INCREASED
    term:
      id: GO:0007259
      label: cell surface receptor signaling pathway via JAK-STAT
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Molecular abnormalities that occur in ANKL can be divided into three
      major groups: JAK/STAT pathway activation, epigenetic dysregulation, and
      impairment of TP53 and DNA repair.
    explanation: >-
      The review identifies JAK/STAT pathway activation as a major molecular
      abnormality in ANKL.
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We study 14 ANKL patients using whole-exome sequencing (WES) and identify
      mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as
      inDDX3X(29%) and epigenetic modifiers (50%).
    explanation: >-
      This human tumor genomic study supports recurrent STAT3 mutation in ANKL.
  downstream:
  - target: Malignant NK-Cell Expansion
    description: JAK-STAT activation sustains proliferation and survival of malignant NK cells.
- name: TP53 and DNA-Repair Impairment
  description: >-
    TP53 mutation, abnormal p53 expression, and broader DNA-repair impairment
    form a distinct pathophysiologic axis in ANKL. These alterations are most
    directly linked to loss of cell-cycle checkpoint and apoptosis control.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  biological_processes:
  - preferred_term: regulation of apoptotic process
    modifier: ABNORMAL
    term:
      id: GO:0042981
      label: regulation of apoptotic process
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Molecular abnormalities that occur in ANKL can be divided into three
      major groups: JAK/STAT pathway activation, epigenetic dysregulation, and
      impairment of TP53 and DNA repair.
    explanation: >-
      The review separates TP53 and DNA-repair impairment from JAK-STAT and
      epigenetic mechanisms.
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2
      mutations were each detected in 2 of 6 cases.
    explanation: >-
      This clinicopathologic series supports recurrent TP53 mutation in ANKL.
  downstream:
  - target: Malignant NK-Cell Expansion
    description: TP53 and DNA-repair impairment can permit survival and expansion of genomically abnormal NK cells.
- name: Epigenetic Modifier Dysregulation
  description: >-
    Epigenetic dysregulation is a distinct recurrent molecular class in ANKL,
    including mutations in epigenetic regulatory genes such as ASXL1 and TET2
    and broader epigenetic-modifier alterations in sequencing cohorts.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Molecular abnormalities that occur in ANKL can be divided into three
      major groups: JAK/STAT pathway activation, epigenetic dysregulation, and
      impairment of TP53 and DNA repair.
    explanation: >-
      The review identifies epigenetic dysregulation as an independent major
      molecular abnormality class in ANKL.
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We study 14 ANKL patients using whole-exome sequencing (WES) and identify
      mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as
      inDDX3X(29%) and epigenetic modifiers (50%).
    explanation: >-
      Whole-exome sequencing supports frequent epigenetic-modifier mutation in
      ANKL tumors.
  downstream:
  - target: Malignant NK-Cell Expansion
    description: Epigenetic dysregulation can alter malignant NK-cell transcriptional control and survival.
- name: HLH-Like Systemic Inflammation and Coagulopathy
  description: >-
    ANKL often manifests as a severe systemic inflammatory syndrome with fever,
    hemophagocytic syndrome or HLH, hepatosplenomegaly, and disseminated
    intravascular coagulation. These complications contribute to early organ
    failure and mortality.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  locations:
  - preferred_term: blood
    term:
      id: UBERON:0000178
      label: blood
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  - preferred_term: spleen
    term:
      id: UBERON:0002106
      label: spleen
  biological_processes:
  - preferred_term: cytokine-mediated signaling pathway
    modifier: INCREASED
    term:
      id: GO:0019221
      label: cytokine-mediated signaling pathway
  - preferred_term: coagulation
    modifier: ABNORMAL
    term:
      id: GO:0050817
      label: coagulation
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients commonly present acutely with fever, constitutional symptoms,
      hepatosplenomegaly, and often disseminated intravascular coagulation or
      hemophagocytic syndrome.
    explanation: >-
      This review directly links the acute ANKL presentation to fever,
      hepatosplenomegaly, DIC, and hemophagocytic syndrome.
histopathology:
- name: Interstitial and Sinusoidal Bone Marrow Involvement
  diagnostic: true
  description: >-
    Bone marrow involvement by ANKL can show interstitial or sinusoidal
    infiltration patterns, supporting a marrow-based leukemic presentation when
    interpreted with NK-cell immunophenotyping.
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two distinct patterns of bone marrow involvement were identified:
      interstitial and sinusoidal.
    explanation: >-
      This clinicopathologic series supports the marrow infiltration patterns as
      a histopathologic feature of ANKL.
phenotypes:
- category: Constitutional
  name: Fever and Constitutional Symptoms
  severity: SEVERE
  description: >-
    Acute fever and systemic constitutional symptoms are part of the typical
    fulminant presentation.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients commonly present acutely with fever, constitutional symptoms,
      hepatosplenomegaly, and often disseminated intravascular coagulation or
      hemophagocytic syndrome.
    explanation: >-
      The abstract explicitly includes fever and constitutional symptoms in the
      common acute presentation.
- category: Organomegaly
  name: Hepatosplenomegaly
  severity: SEVERE
  description: >-
    Concurrent liver and spleen enlargement reflects reticuloendothelial organ
    involvement in the systemic leukemic process.
  phenotype_term:
    preferred_term: Hepatosplenomegaly
    term:
      id: HP:0001433
      label: Hepatosplenomegaly
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients commonly present acutely with fever, constitutional symptoms,
      hepatosplenomegaly, and often disseminated intravascular coagulation or
      hemophagocytic syndrome.
    explanation: >-
      The review abstract directly names hepatosplenomegaly as a common ANKL
      presentation feature.
- category: Hematologic
  name: Disseminated Intravascular Coagulation
  severity: SEVERE
  description: >-
    DIC is a life-threatening coagulopathy reported in the acute ANKL
    presentation and can contribute to organ failure.
  phenotype_term:
    preferred_term: Disseminated intravascular coagulation
    term:
      id: HP:0005521
      label: Disseminated intravascular coagulation
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients commonly present acutely with fever, constitutional symptoms,
      hepatosplenomegaly, and often disseminated intravascular coagulation or
      hemophagocytic syndrome.
    explanation: >-
      The abstract directly supports DIC as a feature of the acute ANKL
      presentation.
- category: Immune
  name: HLH-Like Hemophagocytic Syndrome
  severity: SEVERE
  description: >-
    ANKL can initially mimic or present as EBV-driven HLH, with hemophagocytic
    syndrome reflecting severe macrophage activation and systemic inflammation.
  phenotype_term:
    preferred_term: Hemophagocytosis
    term:
      id: HP:0012156
      label: Hemophagocytosis
  evidence:
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aggressive natural killer cell leukemia (ANKL) is a rare, aggressive
      hematologic malignancy which often presents as fulminant Epstein-Barr
      virus (EBV)- driven hemophagocytic lymphohistiocytosis (HLH).
    explanation: >-
      The case report directly supports EBV-HLH as a frequent and clinically
      important presentation mode for ANKL.
  - reference: DOI:10.24953/turkjpediatr.2024.5072
    reference_title: "Clinicopathological features and treatment of aggressive natural killer cell leukemia: case series and literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HLH can serve as the initial manifestation of ANKL.
    explanation: >-
      The pediatric case series and literature review supports HLH as an initial
      manifestation.
- category: Hematologic
  name: Pancytopenia
  severity: SEVERE
  description: >-
    Cytopenias, including pancytopenia, can accompany the acute leukemic and
    HLH-like presentation of ANKL and should prompt marrow and flow-cytometric
    evaluation when ANKL is suspected.
  phenotype_term:
    preferred_term: Pancytopenia
    term:
      id: HP:0001876
      label: Pancytopenia
  evidence:
  - reference: DOI:10.1155/crh/7796972
    reference_title: "Aggressive Natural Killer Cell Leukemia: A Rare and Rapidly Progressive Hematologic Malignancy—Case Report and Literature Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a case of a 71‐year‐old Caucasian male who developed fever,
      altered mental status, hepatosplenomegaly, pancytopenia, and
      hemophagocytic lymphohistiocytosis (HLH) and who was ultimately diagnosed
      with ANKL.
    explanation: >-
      The case report directly supports pancytopenia as part of an ANKL
      presentation.
genetic:
- name: STAT3
  gene_term:
    preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  association: Recurrent somatic mutation and JAK-STAT pathway activation in ANKL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We study 14 ANKL patients using whole-exome sequencing (WES) and identify
      mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as
      inDDX3X(29%) and epigenetic modifiers (50%).
    explanation: >-
      Whole-exome sequencing of human ANKL tumors identified recurrent STAT3
      mutations.
- name: TP53
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  association: Recurrent TP53 alteration and p53 overexpression in ANKL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2
      mutations were each detected in 2 of 6 cases.
    explanation: >-
      This clinicopathologic series supports recurrent TP53 mutations in ANKL.
- name: DDX3X
  gene_term:
    preferred_term: DDX3X
    term:
      id: hgnc:2745
      label: DDX3X
  association: Recurrent somatic mutation in ANKL genomic profiling
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We study 14 ANKL patients using whole-exome sequencing (WES) and identify
      mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as
      inDDX3X(29%) and epigenetic modifiers (50%).
    explanation: >-
      Whole-exome sequencing of ANKL identified recurrent DDX3X mutation.
- name: ASXL1
  gene_term:
    preferred_term: ASXL1
    term:
      id: hgnc:18318
      label: ASXL1
  association: Epigenetic modifier mutation in ANKL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2
      mutations were each detected in 2 of 6 cases.
    explanation: >-
      This clinicopathologic series supports ASXL1 mutation as a recurrent
      epigenetic modifier lesion in ANKL.
- name: TET2
  gene_term:
    preferred_term: TET2
    term:
      id: hgnc:25941
      label: TET2
  association: Epigenetic modifier mutation in ANKL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2
      mutations were each detected in 2 of 6 cases.
    explanation: >-
      This clinicopathologic series supports TET2 mutation as a recurrent
      epigenetic modifier lesion in ANKL.
progression:
- phase: Fulminant Presentation and Early Mortality
  duration: often weeks to months
  notes: >-
    ANKL frequently progresses rapidly despite intensive therapy, with very
    short median survival reported in clinicopathologic series.
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients had very poor outcomes despite intensive chemotherapy, with a
      median survival of 2 months.
    explanation: >-
      The 12-case series directly supports very poor prognosis and short median
      survival.
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median OS was only 55 days (Supplementary Tables S2) and 1-year
      survival rate was only 4.42% (5/113; Supplementary Fig. S1B), which
      indicated a dismal outcome of ANKL.
    explanation: >-
      The 113-patient multicenter cohort supports extremely poor overall
      survival in ANKL.
diagnosis:
- name: NK-Cell Flow Cytometry and Immunophenotyping
  description: >-
    Diagnosis requires identifying an abnormal NK-cell population and excluding
    T-cell lineage by immunophenotyping. A typical pattern is CD56/CD94-positive
    and surface CD3/CD5/CD57-negative, with cytoplasmic CD3epsilon and cytotoxic
    marker evaluation when available.
  diagnosis_term:
    preferred_term: flow cytometry immunophenotyping
  results: >-
    An atypical CD3-/CD56+ or CD56+/CD94+ NK-cell population in marrow or blood
    supports ANKL in the appropriate clinicopathologic context.
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The neoplastic cells were positive for CD56 and CD94, and negative for
      surface CD3, CD5, and CD57 in all cases assessed.
    explanation: >-
      This case series supports the core diagnostic immunophenotype.
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      bone marrow biopsy demonstrated an atypical CD3-/CD56+ natural killer
      (NK) cell population with diminished CD7 expression consistent with EBV+
      ANKL.
    explanation: >-
      The case report demonstrates diagnostic recognition of ANKL by marrow
      biopsy and NK-cell immunophenotyping.
- name: EBER In Situ Hybridization
  description: >-
    EBER testing helps establish EBV-associated ANKL and distinguish malignant
    NK/T disease from EBV-HLH without an identifiable neoplastic population.
  diagnosis_term:
    preferred_term: EBER in situ hybridization
  results: EBER positivity in malignant NK cells supports EBV-associated ANKL.
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They were also positive for CD2 (10/12), c-MYC (6/8), BCL2 (6/8), CD16
      (5/7), EBER (9/12), CD7 (6/11), pSTAT3Tyr705 (3/8), CD8 (2/6), PD-L1
      (2/8), CD4 (2/11), CD8 (2/6), and CD158 (1/5).
    explanation: >-
      The 12-case series reports EBER positivity in most ANKL cases assessed.
treatments:
- name: Asparaginase- or Pegaspargase-Containing Chemotherapy
  description: >-
    Asparaginase-based regimens, including pegaspargase-containing intensive
    combinations and modified SMILE-like approaches, are commonly considered
    for rapid induction. Evidence remains limited because ANKL is rare and
    outcomes are poor even when responses occur.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
    therapeutic_agent:
    - preferred_term: Pegaspargase
      term:
        id: NCIT:C1200
        label: Pegaspargase
  target_mechanisms:
  - target: Malignant NK-Cell Expansion
    treatment_effect: INHIBITS
    description: Cytotoxic induction chemotherapy attempts to reduce the malignant NK-cell burden.
  evidence:
  - reference: DOI:10.24953/turkjpediatr.2024.5072
    reference_title: "Clinicopathological features and treatment of aggressive natural killer cell leukemia: case series and literature review"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intensive combination chemotherapy based on pegaspargase and
      anthracyclines may be considered for ANKL.
    explanation: >-
      The pediatric case series and literature review supports pegaspargase-
      based chemotherapy as a considered treatment while preserving uncertainty
      in the wording.
  - reference: clinicaltrials:NCT03719105
    reference_title: Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and
      etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in
      children, adolescents, and young adults with advanced stage NK lymphoma
      and leukemia
    explanation: >-
      The active trial summary supports a modified SMILE pegaspargase-containing
      regimen for advanced NK lymphoma/leukemia.
- name: Allogeneic Hematopoietic Stem Cell Transplantation
  description: >-
    Allogeneic hematopoietic stem cell transplantation is considered as
    consolidation for eligible patients who achieve disease response after
    induction therapy.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
  target_mechanisms:
  - target: Malignant NK-Cell Expansion
    treatment_effect: INHIBITS
    description: Transplantation aims to consolidate remission after cytoreduction of the malignant NK-cell clone.
  evidence:
  - reference: DOI:10.24953/turkjpediatr.2024.5072
    reference_title: "Clinicopathological features and treatment of aggressive natural killer cell leukemia: case series and literature review"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Case-2 underwent hematopoietic stem cell transplantation and is currently
      alive and disease-free.
    explanation: >-
      This human case series supports HSCT as a potential consolidation
      strategy, but the single-case nature warrants partial support.
  - reference: clinicaltrials:NCT03719105
    reference_title: Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both groups proceed to allogeneic stem cell transplant with disease
      response.
    explanation: >-
      The trial summary supports HSCT consolidation after disease response.
- name: JAK and BCL2 Inhibition
  description: >-
    JAK inhibitors and BCL2 inhibitors are emerging rational therapies rather
    than established ANKL standards. Their rationale comes from ANKL genomic and
    drug sensitivity profiling showing JAK-STAT pathway involvement and NK-cell
    sensitivity to JAK and BCL2 inhibition.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: JAK-STAT Pathway Activation
    treatment_effect: INHIBITS
    description: JAK inhibition targets recurrent JAK-STAT signaling activity in NK-cell malignancies.
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: >-
      Drug sensitivity profiling further demonstrates the role of the JAK-STAT
      pathway in the pathogenesis of NK-cell malignancies, identifying NK cells
      to be highly sensitive to JAK and BCL2 inhibition compared to other
      hematopoietic cell lineages.
    explanation: >-
      This ex vivo/in vitro drug profiling supports a targeted-therapy
      rationale, but not an established clinical standard for ANKL.
clinical_trials:
- name: NCT03719105
  description: >-
    Pilot chemoimmunotherapy study using modified SMILE-style induction for
    advanced NK lymphoma/leukemia followed by allogeneic stem cell transplant
    for responders.
  evidence:
  - reference: clinicaltrials:NCT03719105
    reference_title: Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and
      etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in
      children, adolescents, and young adults with advanced stage NK lymphoma
      and leukemia
    explanation: >-
      The trial summary directly describes the ANKL-relevant induction regimen
      for advanced NK lymphoma/leukemia.
- name: NCT03623087
  description: >-
    SIMPLE chemotherapy study for NK/T-cell malignancies, derived from a
    PIGLETS chemotherapy protocol used in extranodal NK/T-cell lymphoma and
    aggressive NK leukemia.
  evidence:
  - reference: clinicaltrials:NCT03623087
    reference_title: "Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NK malignancies consist of two different clinical entities, extranodal
      NK/T cell lymphoma and aggressive NK leukaemia.
    explanation: >-
      The trial summary explicitly includes aggressive NK leukemia in the NK
      malignancy population targeted by the chemotherapy study.
- name: NCT05863234
  description: >-
    Phase I/II dose-escalation clinical trial evaluating repeated continuous
    intravenous PPMX-T003 in aggressive NK-cell leukemia.
  evidence:
  - reference: clinicaltrials:NCT05863234
    reference_title: Multicenter, Open-label, Dose-escalation Phase I/II Study to Evaluate the Tolerability, Safety, Efficacy and Pharmacokinetics of Repeated Continuous Intravenous PPMX-T003 in Patients With Aggressive NK Cell Leukaemia (ANKL) (Physician-initiated Clinical Trial)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is Phase I/II Dose-Escalation Study to evaluate the tolerability,
      safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell
      leukemia.
    explanation: >-
      The trial summary directly supports an ANKL-specific PPMX-T003 clinical
      trial.
differential_diagnoses:
- name: EBV-Driven Hemophagocytic Lymphohistiocytosis Without Neoplasia
  description: >-
    EBV-HLH can be the initial presentation of ANKL, but EBV-HLH without a
    malignant NK/T-cell population is a key differential diagnosis during early
    evaluation.
  distinguishing_features:
  - Detection of an atypical CD3-/CD56+ NK-cell population in marrow or blood supports ANKL rather than isolated EBV-HLH.
  evidence:
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This case highlights the diagnostic challenges of ANKL given the lack of
      standardized diagnostic criteria, the importance of considering T/NK cell
      malignancies in the differential diagnosis of EBV-HLH, and adds to the
      literature on this rare disease.
    explanation: >-
      This case report explicitly states that T/NK malignancies must be
      considered in the differential diagnosis of EBV-HLH.
- name: Extranodal NK/T-Cell Lymphoma
  description: >-
    Extranodal NK/T-cell lymphoma is another EBV-associated NK/T malignancy with
    overlapping immunophenotypic and clinical features, especially when
    disseminated. Leukemic blood and marrow involvement support ANKL.
  distinguishing_features:
  - Primary extranodal mass-forming disease favors extranodal NK/T-cell lymphoma; systemic leukemic marrow and blood involvement favors ANKL.
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This acute clinical presentation and the variable pathologic and
      immunophenotypic features of ANKL overlap with other diagnostic entities,
      making it challenging to establish a timely and accurate diagnosis of
      ANKL.
    explanation: >-
      The review supports clinically important diagnostic overlap with other
      NK/T-cell entities.
references:
- reference: DOI:10.3390/cancers12102900
  title: "Aggressive NK Cell Leukemia: Current State of the Art"
  findings: []
- reference: DOI:10.3389/frhem.2024.1413794
  title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
  findings: []
- reference: DOI:10.1097/pas.0000000000001518
  title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
  findings: []
- reference: DOI:10.24953/turkjpediatr.2024.5072
  title: "Clinicopathological features and treatment of aggressive natural killer cell leukemia: case series and literature review"
  findings: []
- reference: DOI:10.1038/s41467-018-03987-2
  title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
  findings: []
- reference: PMID:29263371
  title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
  findings: []
- reference: DOI:10.1155/crh/7796972
  title: "Aggressive Natural Killer Cell Leukemia: A Rare and Rapidly Progressive Hematologic Malignancy—Case Report and Literature Review"
  findings: []
- reference: clinicaltrials:NCT03623087
  title: "Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies"
  findings: []
- reference: clinicaltrials:NCT03719105
  title: Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study
  findings: []
- reference: clinicaltrials:NCT05863234
  title: Multicenter, Open-label, Dose-escalation Phase I/II Study to Evaluate the Tolerability, Safety, Efficacy and Pharmacokinetics of Repeated Continuous Intravenous PPMX-T003 in Patients With Aggressive NK Cell Leukaemia (ANKL) (Physician-initiated Clinical Trial)
  findings: []
notes: >-
  Falcon deep research was completed on 2026-05-11. Final curation emphasized
  sources with generated reference-cache abstracts, PMID full text, or
  ClinicalTrials.gov summaries so evidence snippets can be validated exactly.
  Tang 2017 was promoted from the research artifact into YAML evidence for
  clinical subtype and outcome assertions. Ishida/Sumbly reviews were retained
  in the research artifact but not promoted to YAML evidence because the local
  DOI cache fetch returned metadata-only records for those sources.
📚

References & Deep Research

References

10
DOI:10.3390/cancers12102900
Aggressive NK Cell Leukemia: Current State of the Art
No top-level findings curated for this source.
DOI:10.3389/frhem.2024.1413794
Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent
No top-level findings curated for this source.
DOI:10.1097/pas.0000000000001518
Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
No top-level findings curated for this source.
DOI:10.24953/turkjpediatr.2024.5072
Clinicopathological features and treatment of aggressive natural killer cell leukemia: case series and literature review
No top-level findings curated for this source.
DOI:10.1038/s41467-018-03987-2
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
No top-level findings curated for this source.
PMID:29263371
Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes.
No top-level findings curated for this source.
DOI:10.1155/crh/7796972
Aggressive Natural Killer Cell Leukemia: A Rare and Rapidly Progressive Hematologic Malignancy—Case Report and Literature Review
No top-level findings curated for this source.
clinicaltrials:NCT03623087
Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies
No top-level findings curated for this source.
clinicaltrials:NCT03719105
Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study
No top-level findings curated for this source.
clinicaltrials:NCT05863234
Multicenter, Open-label, Dose-escalation Phase I/II Study to Evaluate the Tolerability, Safety, Efficacy and Pharmacokinetics of Repeated Continuous Intravenous PPMX-T003 in Patients With Aggressive NK Cell Leukaemia (ANKL) (Physician-initiated Clinical Trial)
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Aggressive NK-cell Leukemia (ANKL) — Comprehensive Disease Characteristics Report
Edison Scientific Literature 29 citations 2026-05-11T14:04:19.824446

Aggressive NK-cell Leukemia (ANKL) — Comprehensive Disease Characteristics Report

Target Disease

  • Disease name: Aggressive NK-cell leukemia (ANKL)
  • Category: Mature NK-cell neoplasm; EBV-associated T/NK-cell neoplasia spectrum
  • MONDO ID: Not available from the retrieved sources in this run (needs dedicated ontology lookup outside the current evidence set).

Evidence summary table

Domain Key points Quantitative data Key source (with year, journal) URL
Definition / classification ANKL is a rare, fulminant, systemic mature NK-cell neoplasm with acute presentation and grave prognosis; recent reviews note it remains recognized in modern WHO/ICC-era classification of mature T/NK-cell neoplasms. It is distinct from extranodal NK/T-cell lymphoma, though overlap exists in disseminated disease. (hussein2020aggressivenkcell pages 1-3, spaner2024casereportaggressive pages 1-2, ferry2024maturebt pages 8-10) Median age around 40 years in review cohorts; fewer than 500 cases reported overall in literature summaries. (hussein2020aggressivenkcell pages 1-3, spaner2024casereportaggressive pages 1-2) El Hussein et al., 2020, Cancers; Spaner et al., 2024, Frontiers in Hematology; Ferry et al., 2024, J Hematol Oncol https://doi.org/10.3390/cancers12102900
EBV association EBV is strongly associated with ANKL and is detectable in most cases by EBER; however, EBV-negative ANKL exists and can show similar clinicopathologic features. ANKL often sits within the spectrum of EBV-associated T/NK-cell lymphoproliferative diseases. (hussein2020genomicandimmunophenotypic pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 1-2, hussein2020aggressivenkcell pages 3-5) ~90% EBV-driven in a 2024 case review; ~10% EBV-negative in older review; EBER positive in 9/12 cases in one clinicopathologic series. (spaner2024casereportaggressive pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, hussein2020genomicandimmunophenotypic pages 1-2) Hussein et al., 2020, Am J Surg Pathol; Ishida, 2018, Front Pediatr; Spaner et al., 2024, Front Hematol https://doi.org/10.1097/pas.0000000000001518
Typical presentation / phenotypes Common features include fever, constitutional symptoms, hepatosplenomegaly, liver dysfunction, leukemic blood picture, cytopenias, HLH/hemophagocytosis, DIC/coagulopathy, and multiorgan failure; nasal/skin lesions are less common than marrow, blood, liver, and spleen involvement. (hussein2020aggressivenkcell pages 1-3, ni2024clinicopathologicalfeaturesand pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, spaner2024casereportaggressive pages 1-2) HLH reported in ~60–90% in pediatric case literature summary; in one 12-case series, HLH in 2/12; common involved organs include marrow, peripheral blood, liver, spleen, lymph nodes. (ni2024clinicopathologicalfeaturesand pages 1-2, hussein2020genomicandimmunophenotypic pages 1-2) Ni et al., 2024, Turkish Journal of Pediatrics; El Hussein et al., 2020, Cancers; Ishida, 2018, Front Pediatr https://doi.org/10.24953/turkjpediatr.2024.5072
Diagnostic immunophenotype Characteristic phenotype is NK-lineage with surface CD3 negative and cytoplasmic CD3ε positive; typically CD56+, CD2+, CD94+, cytotoxic marker positive (granzyme B, TIA1, perforin), usually negative for CD4, CD5, CD57, TCR αβ/γδ, and often lacking KIR expression. Bone marrow involvement may be interstitial or sinusoidal/intrasinusoidal. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020aggressivenkcell pages 3-5, hussein2020genomicandimmunophenotypic pages 2-3) In one 12-case series: CD56+ 12/12, CD94+ 9/9, CD2+ 10/12, EBER+ 9/12; negative in all tested for surface CD3 12/12, CD5 11/11, CD57 9/9, TCRαβ 11/11, TCRγδ 11/11. Marrow ANKL fraction ranged 1.5% to 96.4%, median 22.5%. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020genomicandimmunophenotypic pages 2-3) El Hussein et al., 2020, Am J Surg Pathol https://doi.org/10.1097/pas.0000000000001518
Genetics / pathways Recurrent alterations cluster in JAK/STAT activation, epigenetic dysregulation, TP53/DNA-repair impairment, and RAS/MAPK signaling; IL10-STAT3-MYC biosynthetic axis and HACE1 hypermethylation have been implicated. (hussein2020aggressivenkcell pages 1-3, ishida2018aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 1-2, dufva2018aggressivenaturalkillercell pages 3-4) Dufva et al.: STAT3 21%, RAS-MAPK genes 21%, DDX3X 29%, epigenetic modifiers 50%; copy-gain/mutation events affecting JAK2/STAT3/STAT5B also reported. Other summaries report TP53 34%, TET2 28%, CREBBP 21%, MLL2/KMT2D 21%, JAK-STAT pathway alterations ~48%, STAT3 mutations ~17%. (dufva2018aggressivenaturalkillercell pages 3-4, ishida2018aggressivenkcellleukemia pages 1-2, sumbly2022aggressivenaturalkiller pages 2-3) Dufva et al., 2018, Nat Commun; Ishida, 2018, Front Pediatr; Sumbly et al., 2022, Cureus https://doi.org/10.1038/s41467-018-03987-2
Epidemiology / demographics ANKL is very rare, with geographic enrichment in Asian and Central/South American populations; most patients are young to middle-aged adults, though pediatric and older adult cases occur. Male predominance is reported in some cohorts. (hussein2020aggressivenkcell pages 1-3, ishida2018aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 1-2) Chinese multicenter cohort: age peak 21–30 years was 29.2% (33/113); male:female ratio nearly 2:1 in that decade. Western clinicopathologic series: median age 47.5 years, 9 men/3 women. (tang2017aggressivenkcellleukemia pages 1-2, hussein2020genomicandimmunophenotypic pages 1-2) Tang et al., 2017, Blood Cancer Journal; El Hussein et al., 2020, Am J Surg Pathol https://doi.org/10.1038/s41408-017-0021-z
Prognosis Prognosis is extremely poor without effective induction and consolidation; many reviews cite median survival under 2–3 months. A subacute subtype with prolonged prodrome may have better outcomes than classic fulminant ANKL. (hussein2020aggressivenkcell pages 1-3, ni2024clinicopathologicalfeaturesand pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 1-2, spaner2024casereportaggressive pages 1-2) Median OS 55 days and 1-year survival 4.42% (5/113) in a large cohort; median survival 2 months in a 12-case Western series; review summaries report median survival <2 to <3 months. (tang2017aggressivenkcellleukemia pages 1-2, hussein2020genomicandimmunophenotypic pages 1-2, ni2024clinicopathologicalfeaturesand pages 1-2) Tang et al., 2017, Blood Cancer Journal; El Hussein et al., 2020, Am J Surg Pathol; Ni et al., 2024, Turkish Journal of Pediatrics https://doi.org/10.1038/s41408-017-0021-z
Treatment: asparaginase-based therapy Anthracycline-only approaches are generally ineffective; L-asparaginase/pegaspargase-containing regimens are the main active induction strategy. Regimens used include SMILE, AspaMetDex, L-GemOx, and related protocols. (ni2024clinicopathologicalfeaturesand pages 1-2, tang2017aggressivenkcellleukemia pages 1-2) In Tang et al., among 13 newly diagnosed patients treated with AspaMetDex alone: CR 30.77% (4/13), ORR 76.92% (10/13), median OS 115 days; grade 3–4 hematologic AEs in 53.84% (7/13). Ni et al. summarize chemotherapy CR rate as <36%. (tang2017aggressivenkcellleukemia pages 1-2, ni2024clinicopathologicalfeaturesand pages 1-2) Tang et al., 2017, Blood Cancer Journal; Ni et al., 2024, Turkish Journal of Pediatrics https://doi.org/10.1038/s41408-017-0021-z
Treatment: allo-HSCT / outcomes Allogeneic HSCT is the only modality consistently associated with durable survival in fit responders and is typically pursued after remission induction with asparaginase-based chemotherapy. (tang2017aggressivenkcellleukemia pages 1-2, ni2024clinicopathologicalfeaturesand pages 1-2) In Tang et al., 7 patients underwent allo-HSCT after CR; median time to transplant 73 days, median OS 300 days, 2-year OS 42.86% (3/7). Ni et al. summarize ~55.5% relapse/progression within 1 year after allo-HSCT. (tang2017aggressivenkcellleukemia pages 1-2, ni2024clinicopathologicalfeaturesand pages 1-2) Tang et al., 2017, Blood Cancer Journal; Ni et al., 2024, Turkish Journal of Pediatrics https://doi.org/10.1038/s41408-017-0021-z
Emerging / targeted therapy rationale Genomic profiling and drug sensitivity studies support investigation of JAK inhibitors, BCL2 inhibition, and immune checkpoint blockade in selected cases, especially where JAK/STAT activation or PD-L1 expression is present. These remain emerging rather than standard ANKL therapies. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020aggressivenkcell pages 1-3, dufva2018aggressivenaturalkillercell pages 3-4) pSTAT3 positivity in 3/8 and PD-L1 positivity in 2/8 in one immunophenotypic series; Dufva et al. found NK malignancies highly sensitive to JAK and BCL2 inhibition in drug profiling. (hussein2020genomicandimmunophenotypic pages 1-2, dufva2018aggressivenaturalkillercell pages 3-4) El Hussein et al., 2020, Am J Surg Pathol; Dufva et al., 2018, Nat Commun https://doi.org/10.1038/s41467-018-03987-2

Table: This table condenses core disease facts for aggressive NK-cell leukemia, including classification, EBV association, presentation, diagnostic phenotype, genomics, prognosis, and treatment outcomes. It is useful as a quick evidence-backed reference for building a disease knowledge base entry.

1. Disease information

1.1 Concise overview (current understanding)

Aggressive NK-cell leukemia (ANKL) is a rare, fulminant systemic malignancy of mature natural killer (NK) cells with acute presentation, frequent cytokine-driven inflammatory complications (e.g., HLH), and very poor survival without rapid disease control and consolidation. Reviews emphasize that its acute clinical syndrome overlaps with other entities (notably EBV-associated lymphoproliferative disorders and NK/T-cell lymphomas), complicating early recognition and resulting in delayed diagnosis and treatment. (hussein2020aggressivenkcell pages 1-3, spaner2024casereportaggressive pages 1-2)

Direct abstract quote (example): “Aggressive natural killer cell leukemia (ANKL) is a rare, aggressive hematologic malignancy which often presents as fulminant Epstein-Barr virus (EBV)- driven hemophagocytic lymphohistiocytosis (HLH).” (spaner2024casereportaggressive pages 1-2)

1.2 Key identifiers and ontologies

  • WHO/ICC framing: The current hematopathology ecosystem includes WHO-HAEM5 (2022) and ICC (2022); comparative reviews summarize entity families and naming across systems. A classification comparison review provides the context that WHO-HAEM5 and ICC are the operative modern frameworks for mature B/T/NK neoplasms, and that EBV-positive T/NK entities are explicitly treated as a family. (ferry2024maturebt pages 8-10)
  • ICD/MeSH/OMIM/Orphanet: Not extractable from the current retrieved evidence set; these require targeted queries to OMIM/Orphanet/MeSH.

1.3 Synonyms / alternative names

  • “Aggressive NK-cell leukemia” (most common)
  • “Aggressive NK-cell leukaemia” (UK spelling)
  • Some literature uses “aggressive NK-cell leukemia/lymphoma” in broader discussions of NK-cell malignancies. (ishida2018aggressivenkcellleukemia pages 1-2, NCT03623087 chunk 1)

1.4 Evidence source types in this report

  • Aggregated disease-level resources: pathology/oncology reviews and classification comparison reviews (hussein2020aggressivenkcell pages 1-3, ferry2024maturebt pages 8-10)
  • Human clinical primary studies: multicenter cohort (n=113) (tang2017aggressivenkcellleukemia pages 1-2), clinicopathologic series with IHC/NGS (n=12) (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020genomicandimmunophenotypic pages 2-3)
  • Human genomic/translational primary studies: WES + drug profiling (n=14) (dufva2018aggressivenaturalkillercell pages 3-4, dufva2018aggressivenaturalkillercell media 01c6d37e, dufva2018aggressivenaturalkillercell media 2b03bded)
  • Case-based recent literature (2024): adolescent/pediatric cases emphasizing HLH and diagnostic delays (ni2024clinicopathologicalfeaturesand pages 1-2, spaner2024casereportaggressive pages 1-2)

2. Etiology

2.1 Disease causal factors

Epstein–Barr virus (EBV) association

ANKL is commonly EBV-associated, with EBER positivity in the majority of cases in multiple series, and many reviews describing EBV as a driver in ~90% of cases (though EBV-negative ANKL exists). (hussein2020genomicandimmunophenotypic pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, spaner2024casereportaggressive pages 1-2)

  • Clinicopathologic series: EBER was positive in 9/12 ANKL cases. (hussein2020genomicandimmunophenotypic pages 1-2)
  • Review synthesis: ~10% EBV-negative in one review; EBV-negative cases may present in middle-aged adults and can resemble EBV-positive ANKL clinically/pathologically. (ishida2018aggressivenkcellleukemia pages 1-2, sumbly2022aggressivenaturalkiller pages 2-3)

2.2 Risk factors

  • Geography/ancestry: Cohort and review literature repeatedly notes predilection for Asian populations and Central/South America, consistent with EBV-associated NK/T neoplasia geography. (hussein2020aggressivenkcell pages 1-3, tang2017aggressivenkcellleukemia pages 1-2)
  • Pre-existing EBV-associated immune dysregulation: Several 2024 reports frame ANKL as arising in/with EBV-driven HLH contexts and discuss overlap with chronic active EBV disease in differential diagnosis. (spaner2024casereportaggressive pages 1-2)

Note: Specific germline genetic susceptibility loci or robust environmental risk factors were not retrievable from the current evidence set.

2.3 Protective factors

No protective factors (genetic or environmental) were identified in the retrieved evidence.

2.4 Gene–environment interactions

Not established in retrieved evidence; EBV infection is a biological exposure interacting with host immune status and tumor genetics, but formal GxE data were not found here.

3. Phenotypes (clinical features)

3.1 Core phenotype spectrum

ANKL commonly presents with an acute systemic inflammatory and hematologic syndrome including: - Fever / constitutional symptoms (symptom) - Hepatosplenomegaly (clinical sign) - Cytopenias and leukemic blood picture (laboratory abnormality) - Liver dysfunction / acute liver injury (laboratory and organ phenotype) - Coagulopathy / DIC (laboratory abnormality, complication) - Hemophagocytic lymphohistiocytosis (HLH) (immune dysregulation syndrome) - Multiorgan failure in severe/refractory disease These are repeatedly highlighted across reviews, cohorts, and 2024 case literature. (hussein2020aggressivenkcell pages 1-3, ni2024clinicopathologicalfeaturesand pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, spaner2024casereportaggressive pages 1-2, hussein2020genomicandimmunophenotypic pages 2-3)

Direct abstract quotes (examples): - “Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome.” (sumbly2022aggressivenaturalkiller pages 2-3) - “HLH can serve as the initial manifestation of ANKL.” (ni2024clinicopathologicalfeaturesand pages 1-2)

3.2 Age of onset, severity, progression

  • Typical onset: young to middle-aged adults; however, pediatric/adolescent cases occur. (ni2024clinicopathologicalfeaturesand pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 1-2)
  • Course: fulminant/rapidly progressive in most patients; a “subacute” clinical subtype with prolonged IM-like prodrome (>90 days; median 115 days) was identified in a large cohort. (tang2017aggressivenkcellleukemia pages 2-4)

3.3 Frequency (where available)

  • HLH frequency: A 2024 pediatric-focused review notes HLH is common; in a separate case-literature preprint, HLH co-occurrence is described as frequent; quantitative, cohort-level HLH prevalence was not consistently extractable from all sources here. (ni2024clinicopathologicalfeaturesand pages 1-2)

3.4 Quality of life impact

Formal QoL instruments (EQ-5D/SF-36/PROMIS) were not identified in retrieved evidence. Clinical impact is inferred from fulminant symptoms, ICU-level complications (DIC, multiorgan failure), and extremely short survival. (hussein2020aggressivenkcell pages 1-3, tang2017aggressivenkcellleukemia pages 1-2)

3.5 Suggested HPO terms (non-exhaustive)

  • Fever HP:0001945
  • Hepatosplenomegaly HP:0001433 (or hepatomegaly HP:0002240; splenomegaly HP:0001744)
  • Pancytopenia HP:0001876
  • Thrombocytopenia HP:0001873
  • Elevated lactate dehydrogenase HP:0003236
  • Disseminated intravascular coagulation HP:0001907
  • Hemophagocytic lymphohistiocytosis HP:0031425
  • Acute liver failure HP:0006557 / abnormal liver function tests HP:0002910

4. Genetic / molecular information

4.1 Causal genes

ANKL is not a monogenic germline disorder in the retrieved evidence. It is characterized by somatic alterations and pathway dysregulation.

4.2 Recurrently altered genes and pathways (with frequencies)

Multiple sources converge on three major molecular themes: JAK/STAT activation, epigenetic dysregulation, and TP53/DNA repair impairment, with additional contribution from RAS/MAPK signaling. (hussein2020aggressivenkcell pages 1-3, dufva2018aggressivenaturalkillercell pages 3-4)

JAK/STAT pathway

  • WES study (n=14): STAT3 mutations ~21%; copy-number and other alterations implicating JAK/STAT signaling were emphasized. (dufva2018aggressivenaturalkillercell pages 3-4)
  • Review synthesis: JAK-STAT pathway alterations reported ~48% overall in some summaries. (sumbly2022aggressivenaturalkiller pages 2-3)

Visual evidence from Dufva et al. shows JAK-STAT component alterations and copy-number gains and summarizes frequencies across cohorts (including JAK2/STAT3/STAT5 alterations). (dufva2018aggressivenaturalkillercell media 01c6d37e, dufva2018aggressivenaturalkillercell media 2b03bded)

Epigenetic modifiers

  • WES study: epigenetic modifier mutations reported in ~50%. (dufva2018aggressivenaturalkillercell pages 3-4)
  • Review synthesis lists TET2 (28%), CREBBP (21%), MLL2/KMT2D (21%) among recurrent events in a summarized cohort. (sumbly2022aggressivenaturalkiller pages 2-3, ishida2018aggressivenkcellleukemia pages 1-2)

TP53 pathway

  • Review synthesis reports TP53 mutations ~34%. (sumbly2022aggressivenaturalkiller pages 2-3, ishida2018aggressivenkcellleukemia pages 1-2)
  • A large cohort found TP53 mutations enriched in classic (fulminant) ANKL (37.93%, 11/29 in sequenced classic ANKL), absent in subacute ANKL subtype in that cohort’s sequencing subset. (tang2017aggressivenkcellleukemia pages 2-4)
  • Clinicopathologic series: aberrant p53 expression was common (7/8 by IHC), with TP53 mutations detected in 3/6 in the NGS subset. (hussein2020genomicandimmunophenotypic pages 1-2)

DDX3X and RAS/MAPK

  • WES study: DDX3X ~29%, RAS-MAPK pathway genes ~21%. (dufva2018aggressivenaturalkillercell pages 3-4)

4.3 Epigenetics

ANKL epigenetic dysregulation is supported by recurrent mutations in epigenetic modifiers and literature noting methylation events (e.g., HACE1 hypermethylation mentioned in the large cohort background). (tang2017aggressivenkcellleukemia pages 1-2, hussein2020aggressivenkcell pages 1-3)

4.4 Chromosomal abnormalities

Clonal cytogenetic abnormalities are reported in clinical series (5/12 in one series). (hussein2020genomicandimmunophenotypic pages 1-2)

4.5 Mechanistic chain (pathophysiology synthesis)

A plausible causal chain supported by current evidence is: 1) EBV infection of NK lineage cells (EBER+) and/or host immune dysregulation contributes to transformation and/or inflammatory phenotype. (hussein2020genomicandimmunophenotypic pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2) 2) Somatic alterations (JAK/STAT activation; epigenetic modifier and TP53 pathway lesions; RAS/MAPK) promote malignant proliferation, survival, and immune evasion. (dufva2018aggressivenaturalkillercell pages 3-4, tang2017aggressivenkcellleukemia pages 2-4) 3) NK-cell cytokine programs and pathway-driven transcriptional changes (including IL10–STAT3–MYC axis described in reviews) contribute to “cytokine storm” physiology and HLH-like systemic inflammation. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020aggressivenkcell pages 3-5) 4) Downstream manifestations include cytopenias, HLH, DIC, liver dysfunction, and multiorgan failure, driving high early mortality. (hussein2020aggressivenkcell pages 1-3, tang2017aggressivenkcellleukemia pages 1-2)

4.6 Suggested ontology terms

  • GO biological process (examples): JAK-STAT cascade (GO:0007259), cytokine-mediated signaling pathway (GO:0019221), regulation of apoptotic process (GO:0042981), leukocyte proliferation (GO:0070661)
  • Cell Ontology (CL) (examples): natural killer cell CL:0000623; malignant NK cell (no single CL term; represent as NK cell + neoplastic context)

5. Environmental information

Infectious agents

  • EBV (Epstein–Barr virus) is the central infectious association; tumor EBER positivity is common. (hussein2020genomicandimmunophenotypic pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2)

Other environmental and lifestyle associations were not identified in retrieved evidence.

6. Mechanism / pathophysiology

6.1 Molecular pathways (high-confidence)

  • JAK/STAT signaling activation as a recurring pathway with STAT3/STAT5 and copy-number events. (dufva2018aggressivenaturalkillercell pages 3-4, dufva2018aggressivenaturalkillercell media 01c6d37e, dufva2018aggressivenaturalkillercell media 2b03bded)
  • Epigenetic dysregulation (TET2/CREBBP/KMT2D and other epigenetic modifiers). (sumbly2022aggressivenaturalkiller pages 2-3, dufva2018aggressivenaturalkillercell pages 3-4)
  • TP53 impairment (mutation and/or aberrant protein expression). (hussein2020genomicandimmunophenotypic pages 1-2, tang2017aggressivenkcellleukemia pages 2-4)
  • RAS/MAPK activation subset. (dufva2018aggressivenaturalkillercell pages 3-4)

6.2 Immune involvement

ANKL frequently presents with HLH and systemic inflammation; NK lineage biology (cytokine secretion programs) is implicated as a contributor to cytokine storm physiology in reviews. (hussein2020aggressivenkcell pages 3-5, spaner2024casereportaggressive pages 1-2)

6.3 Molecular profiling / multi-omics

  • Genomics: WES and targeted sequencing characterize recurrent pathways; Dufva et al. provides integrated genomics + drug sensitivity profiling highlighting pathway vulnerabilities. (dufva2018aggressivenaturalkillercell pages 3-4)

Not found in retrieved evidence: single-cell or spatial transcriptomics dedicated to ANKL.

7. Anatomical structures affected

7.1 Organ level

Commonly involved sites include bone marrow and peripheral blood, with frequent involvement of liver and spleen; lymph nodes may be involved; less commonly skin/soft tissue/lung are described in recent pediatric case review. (ni2024clinicopathologicalfeaturesand pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2)

7.2 Tissue/cell level

  • Targeted population: neoplastic NK cells infiltrating marrow and other organs. (hussein2020genomicandimmunophenotypic pages 1-2)

7.3 Suggested UBERON terms (examples)

  • Bone marrow: UBERON:0002371
  • Spleen: UBERON:0002106
  • Liver: UBERON:0002107
  • Peripheral blood: UBERON:0000178

8. Temporal development

8.1 Onset pattern

Often acute with rapidly progressive systemic illness prompting “acute leukemia” evaluation. (hussein2020genomicandimmunophenotypic pages 2-3)

8.2 Progression

A large cohort distinguished: - Classic ANKL: fulminant presentation and very short OS. - Subacute ANKL subtype: prolonged prodromal IM-like phase >90 days (median 115 days) before fulminant onset, with survival advantage and differing TP53 mutation enrichment. (tang2017aggressivenkcellleukemia pages 2-4)

9. Inheritance and population

9.1 Epidemiology

Robust population incidence/prevalence rates were not found in the retrieved evidence (likely due to rarity and registry limitations). The largest cohort notes extreme rarity (hundreds of cases in the literature) and geographic predilection. (tang2017aggressivenkcellleukemia pages 1-2, hussein2020aggressivenkcell pages 1-3)

9.2 Demographics (quantitative)

  • Age peak: 21–30 years accounted for 29.2% (33/113) in a multicenter Chinese cohort. (tang2017aggressivenkcellleukemia pages 1-2)
  • Sex: male:female ratio nearly 2:1 in that decade in the same cohort. (tang2017aggressivenkcellleukemia pages 1-2)
  • Western series: median age 47.5 years; 9 men and 3 women. (hussein2020genomicandimmunophenotypic pages 2-3)

9.3 Inheritance

No germline inheritance pattern is established in retrieved evidence; ANKL is characterized by somatic oncogenic alterations.

10. Diagnostics

10.1 Diagnostic approach (real-world)

ANKL diagnosis is challenging due to variable morphology and lack of a single defining marker; it requires integration of: - Peripheral blood and bone marrow morphology - Flow cytometry (NK immunophenotype) - EBV testing (EBER ISH) - IHC and NGS when feasible In a clinicopathologic series, the acute presentation triggered marrow sampling with suspicion of acute leukemia. (hussein2020genomicandimmunophenotypic pages 2-3)

10.2 Immunophenotype (high-yield diagnostic signature)

Across series and reviews, a core pattern includes: - Positive: CD56, CD94, CD2; cytotoxic markers (granzyme B, TIA-1, perforin); often EBER+ (EBV-associated subset) - Negative: surface CD3, CD4, CD5, CD57; TCRαβ/γδ - Bone marrow patterns: interstitial or intrasinusoidal/sinusoidal infiltration patterns. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020aggressivenkcell pages 3-5, hussein2020genomicandimmunophenotypic pages 2-3)

Quantitative immunophenotype from a 12-case series: CD56+ (12/12), CD94+ (9/9), CD2+ (10/12), EBER+ (9/12); surface CD3− (12/12), CD5− (11/11), CD57− (9/9), TCRαβ− (11/11), TCRγδ− (11/11). (hussein2020genomicandimmunophenotypic pages 1-2)

10.3 Differential diagnosis (examples)

  • EBV-driven HLH without neoplasia vs ANKL presenting as EBV-HLH (emphasized in 2024 adolescent case literature). (spaner2024casereportaggressive pages 1-2)
  • Extranodal NK/T-cell lymphoma with leukemic/disseminated phase (clinical overlap discussed in reviews). (hussein2020aggressivenkcell pages 1-3)

10.4 Suggested tests / biomarkers

  • EBER ISH in marrow/tissue
  • Flow cytometry with NK markers (CD56, CD94, CD16, CD2; absence of surface CD3/TCR)
  • Plasma EBV DNA (used in related NK/T malignancies; specific ANKL thresholds not established in retrieved evidence)

11. Outcome / prognosis

11.1 Key statistics

  • Median overall survival: 55 days in a multicenter cohort (n=113). (tang2017aggressivenkcellleukemia pages 1-2)
  • 1-year survival: 4.42% (5/113) in that cohort. (tang2017aggressivenkcellleukemia pages 1-2)
  • Median survival ~2 months: reported in a Western clinicopathologic series and cited broadly in reviews. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020aggressivenkcell pages 1-3)

11.2 Prognostic factors (reported)

Univariate/multivariate analyses in the large cohort identified clinical subtype, LDH, and treatment modality as prognostic; administration of L-asparaginase-based chemotherapy and allo-HSCT were associated with improved survival. (tang2017aggressivenkcellleukemia pages 2-4)

12. Treatment

12.1 Standard practice (current real-world implementation)

Evidence across cohorts/reviews supports: 1) L-asparaginase (or pegylated asparaginase)–containing induction chemotherapy (e.g., SMILE, AspaMetDex, related regimens) 2) Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in eligible responders Despite these strategies, outcomes remain poor for many patients due to rapid progression and treatment-related toxicity in critically ill presentations. (ni2024clinicopathologicalfeaturesand pages 1-2, tang2017aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 2-4)

12.2 Chemotherapy outcomes (quantitative)

In Tang et al. (n=113 cohort), among 13 newly diagnosed patients treated with AspaMetDex chemotherapy alone: - CR: 30.77% (4/13) - ORR: 76.92% (10/13) - Median OS: 115 days (range 37–450) - Grade 3–4 hematologic AEs: 53.84% (7/13) These data highlight that responses are achievable, but durability is limited without consolidation. (tang2017aggressivenkcellleukemia pages 2-4)

A 2024 pediatric case review notes chemotherapy CR rates overall as <36% and summarizes that allo-HSCT still has high relapse/progression within 1 year (~55.5%). (ni2024clinicopathologicalfeaturesand pages 1-2)

12.3 Allo-HSCT outcomes (quantitative)

In Tang et al., 7 patients underwent allo-HSCT after CR: - Median OS: 300 days (range 174–1480) - 2-year OS: 42.86% (3/7) This supports allo-HSCT as a key consolidation strategy when remission is achieved and a donor is available. (tang2017aggressivenkcellleukemia pages 2-4)

12.4 Emerging/targeted therapies (expert analysis)

Genomic and drug profiling evidence indicates potential vulnerabilities: - JAK inhibition (for JAK/STAT-activated disease) - BCL2 inhibition (drug sensitivity profiling highlighted NK cells’ sensitivity) - Immune checkpoint blockade in selected contexts (PD-L1 expression reported in a subset) These approaches are not yet established as standard-of-care in the retrieved evidence but are rationally motivated by the genomic landscape. (hussein2020genomicandimmunophenotypic pages 1-2, dufva2018aggressivenaturalkillercell pages 3-4)

12.5 Clinical trials (NCT identifiers)

  • NCT03719105 (start 2019-03-01; Early Phase 1; Recruiting): Modified SMILE (mSMILE) including calaspargase pegol; pembrolizumab added for <CR after 2 cycles; followed by allo-HSCT when possible; explicitly includes ANKL in cohort 1. (NCT03719105 chunk 1)
  • URL: https://clinicaltrials.gov/study/NCT03719105
  • NCT03623087 (start 2017-07-01; Phase 3; status uncertain in record): “SIMPLE” chemotherapy regimen (cisplatin, gemcitabine, ifosfamide, etoposide, L-asparaginase, dexamethasone) designed as non-inferiority vs SMILE and includes aggressive NK leukaemia among target conditions. (NCT03623087 chunk 1)
  • URL: https://clinicaltrials.gov/study/NCT03623087
  • NCT05863234 (2023; Phase I/II; Recruiting; n=7): PPMX-T003 continuous IV administration safety/PK study in ANKL; excludes patients eligible for chemotherapy. (NCT05863234 chunk 1)
  • URL: https://clinicaltrials.gov/study/NCT05863234

12.6 Suggested MAXO terms (examples)

  • Chemotherapy MAXO:0000647
  • L-asparaginase therapy (map as chemotherapy + specific drug exposure; MAXO may not have a dedicated asparaginase term)
  • Allogeneic hematopoietic stem cell transplantation MAXO:0000747 (or closest HSCT term depending on MAXO release)
  • Immune checkpoint inhibitor therapy (immunotherapy; PD-1 inhibitor)

13. Prevention

No primary prevention strategies are established for ANKL in retrieved evidence. Prevention is largely not applicable beyond general EBV disease management and immunosuppression/immune dysregulation surveillance in high-risk contexts (not quantified here).

14. Other species / natural disease

No naturally occurring veterinary analogs were identified in retrieved evidence.

15. Model organisms

No dedicated animal models were identified in the retrieved evidence. The strongest mechanistic evidence here is from human tumor genomics and ex vivo drug sensitivity profiling. (dufva2018aggressivenaturalkillercell pages 3-4)

Recent developments & 2023–2024 highlights (prioritized)

1) 2024 case-based literature emphasizes that ANKL may present as refractory EBV-HLH and that lack of a “distinct immunologic and morphologic signature” delays diagnosis; early, repeated marrow/peripheral blood flow cytometry is highlighted as critical. (spaner2024casereportaggressive pages 1-2) 2) 2024 pediatric case series supports the operational treatment strategy of intensive pegaspargase/anthracycline-containing chemotherapy with consideration of HSCT, while underscoring high early mortality (e.g., tumor lysis) and the need for rapid supportive care. (ni2024clinicopathologicalfeaturesand pages 1-2) 3) WHO/ICC-era classification synthesis (2024) provides clinicians/pathologists a consolidated view of how modern frameworks align, improving standardization of terminology and diagnostic categorization for mature T/NK neoplasms. (ferry2024maturebt pages 8-10)

Key statistics (for knowledge base)

  • Median OS: 55 days (Tang et al., 2017; n=113). (tang2017aggressivenkcellleukemia pages 1-2)
  • 1-year survival: 4.42% (5/113). (tang2017aggressivenkcellleukemia pages 1-2)
  • AspaMetDex induction (subset): CR 30.77%; ORR 76.92%; median OS 115 days; grade 3–4 hematologic AEs 53.84%. (tang2017aggressivenkcellleukemia pages 2-4)
  • Allo-HSCT (subset): 2-year OS 42.86% (3/7). (tang2017aggressivenkcellleukemia pages 2-4)

Visual evidence (genomic landscape)

Dufva et al. provide figure panels and a table summarizing JAK-STAT pathway alterations (mutations and copy-number gains) across ANKL cohorts and related NK/T malignancies; these visuals support the centrality of JAK/STAT dysregulation in ANKL and the rationale for pathway-directed therapy hypotheses. (dufva2018aggressivenaturalkillercell media 01c6d37e, dufva2018aggressivenaturalkillercell media 2b03bded)

Limitations of this evidence set

  • Several requested identifiers (MONDO, OMIM, Orphanet, MeSH, ICD-10/ICD-11) were not available from the retrieved texts in this run.
  • Many articles in this run do not provide PMIDs in the extracted text, so PMID-preferring citations cannot always be satisfied without additional PubMed-specific retrieval.
  • Incidence/prevalence rates and validated QoL measures were not found in the retrieved evidence.

References

  1. (hussein2020aggressivenkcell pages 1-3): Siba El Hussein, L. Medeiros, and Joseph Khoury. Aggressive nk cell leukemia: current state of the art. Cancers, 12:2900, Oct 2020. URL: https://doi.org/10.3390/cancers12102900, doi:10.3390/cancers12102900. This article has 67 citations.

  2. (spaner2024casereportaggressive pages 1-2): Caroline Spaner, Jessica Durkee-Shock, Andrew Weng, Ryan Stubbins, Alina S. Gerrie, Stefania Pittaluga, Jeffrey I. Cohen, and Luke Y. C. Chen. Case report: aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent. Frontiers in Hematology, Jul 2024. URL: https://doi.org/10.3389/frhem.2024.1413794, doi:10.3389/frhem.2024.1413794. This article has 0 citations.

  3. (ferry2024maturebt pages 8-10): Judith A. Ferry, Brian Hill, and Eric D. Hsi. Mature b, t and nk-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the world health organization and international consensus classification. Journal of Hematology & Oncology, Jul 2024. URL: https://doi.org/10.1186/s13045-024-01570-5, doi:10.1186/s13045-024-01570-5. This article has 19 citations and is from a domain leading peer-reviewed journal.

  4. (hussein2020genomicandimmunophenotypic pages 1-2): Siba El Hussein, Keyur P. Patel, Hong Fang, Beenu Thakral, Sanam Loghavi, Rashmi Kanagal-Shamanna, Sergej Konoplev, Elias J. Jabbour, L. Jeffrey Medeiros, and Joseph D. Khoury. Genomic and immunophenotypic landscape of aggressive nk-cell leukemia. The American Journal of Surgical Pathology, 44:1235-1243, Jun 2020. URL: https://doi.org/10.1097/pas.0000000000001518, doi:10.1097/pas.0000000000001518. This article has 46 citations.

  5. (ishida2018aggressivenkcellleukemia pages 1-2): Fumihiro Ishida. Aggressive nk-cell leukemia. Frontiers in Pediatrics, Oct 2018. URL: https://doi.org/10.3389/fped.2018.00292, doi:10.3389/fped.2018.00292. This article has 66 citations.

  6. (tang2017aggressivenkcellleukemia pages 1-2): Yuan Tang, D. Wang, H. Luo, M. Xiao, H-S Zhou, D. Liu, Shaoping Ling, N. Wang, X-L Hu, Y. Luo, X. Mao, Q. Ao, J. Huang, W. Zhang, L. Sheng, L. Zhu, Z. Shang, L. Gao, P-L Zhang, M. Zhou, K. Zhou, L. Qiu, Q.‐F. Liu, H.-Y. Zhang, J. Li, J. Jin, L. Fu, W-L Zhao, J-P Chen, X. Du, G. Huang, Q-f Wang, J. Zhou, and L. Huang. Aggressive nk-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer Journal, Dec 2017. URL: https://doi.org/10.1038/s41408-017-0021-z, doi:10.1038/s41408-017-0021-z. This article has 72 citations and is from a domain leading peer-reviewed journal.

  7. (hussein2020aggressivenkcell pages 3-5): Siba El Hussein, L. Medeiros, and Joseph Khoury. Aggressive nk cell leukemia: current state of the art. Cancers, 12:2900, Oct 2020. URL: https://doi.org/10.3390/cancers12102900, doi:10.3390/cancers12102900. This article has 67 citations.

  8. (ni2024clinicopathologicalfeaturesand pages 1-2): Yongan Ni, Lei Li, Yuping Wang, and Lirong Sun. Clinicopathological features and treatment of aggressive natural killer cell leukemia: case series and literature review. The Turkish journal of pediatrics, 66 4:481-489, Oct 2024. URL: https://doi.org/10.24953/turkjpediatr.2024.5072, doi:10.24953/turkjpediatr.2024.5072. This article has 1 citations.

  9. (hussein2020genomicandimmunophenotypic pages 2-3): Siba El Hussein, Keyur P. Patel, Hong Fang, Beenu Thakral, Sanam Loghavi, Rashmi Kanagal-Shamanna, Sergej Konoplev, Elias J. Jabbour, L. Jeffrey Medeiros, and Joseph D. Khoury. Genomic and immunophenotypic landscape of aggressive nk-cell leukemia. The American Journal of Surgical Pathology, 44:1235-1243, Jun 2020. URL: https://doi.org/10.1097/pas.0000000000001518, doi:10.1097/pas.0000000000001518. This article has 46 citations.

  10. (dufva2018aggressivenaturalkillercell pages 3-4): Olli Dufva, Matti Kankainen, Tiina Kelkka, Nodoka Sekiguchi, Shady Adnan Awad, Samuli Eldfors, Bhagwan Yadav, Heikki Kuusanmäki, Disha Malani, Emma I Andersson, Paavo Pietarinen, Leena Saikko, Panu E. Kovanen, Teija Ojala, Dean A. Lee, Thomas P. Loughran, Hideyuki Nakazawa, Junji Suzumiya, Ritsuro Suzuki, Young Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Tero Aittokallio, Wing C. Chan, Koichi Ohshima, Fumihiro Ishida, and Satu Mustjoki. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight jak-stat signaling as therapeutic target. Nature Communications, Apr 2018. URL: https://doi.org/10.1038/s41467-018-03987-2, doi:10.1038/s41467-018-03987-2. This article has 163 citations and is from a highest quality peer-reviewed journal.

  11. (sumbly2022aggressivenaturalkiller pages 2-3): Vikram Sumbly, Mallorie Vest, and Ian Landry. Aggressive natural killer cell leukemia: a brief overview of its genomic landscape, histological features, and current management. Cureus, Feb 2022. URL: https://doi.org/10.7759/cureus.22537, doi:10.7759/cureus.22537. This article has 17 citations.

  12. (NCT03623087 chunk 1): Professor Yok-lam Kwong. SIMPLE Chemotherapy for NK Lymphoma/Leukaemia. The University of Hong Kong. 2017. ClinicalTrials.gov Identifier: NCT03623087

  13. (dufva2018aggressivenaturalkillercell media 01c6d37e): Olli Dufva, Matti Kankainen, Tiina Kelkka, Nodoka Sekiguchi, Shady Adnan Awad, Samuli Eldfors, Bhagwan Yadav, Heikki Kuusanmäki, Disha Malani, Emma I Andersson, Paavo Pietarinen, Leena Saikko, Panu E. Kovanen, Teija Ojala, Dean A. Lee, Thomas P. Loughran, Hideyuki Nakazawa, Junji Suzumiya, Ritsuro Suzuki, Young Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Tero Aittokallio, Wing C. Chan, Koichi Ohshima, Fumihiro Ishida, and Satu Mustjoki. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight jak-stat signaling as therapeutic target. Nature Communications, Apr 2018. URL: https://doi.org/10.1038/s41467-018-03987-2, doi:10.1038/s41467-018-03987-2. This article has 163 citations and is from a highest quality peer-reviewed journal.

  14. (dufva2018aggressivenaturalkillercell media 2b03bded): Olli Dufva, Matti Kankainen, Tiina Kelkka, Nodoka Sekiguchi, Shady Adnan Awad, Samuli Eldfors, Bhagwan Yadav, Heikki Kuusanmäki, Disha Malani, Emma I Andersson, Paavo Pietarinen, Leena Saikko, Panu E. Kovanen, Teija Ojala, Dean A. Lee, Thomas P. Loughran, Hideyuki Nakazawa, Junji Suzumiya, Ritsuro Suzuki, Young Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Tero Aittokallio, Wing C. Chan, Koichi Ohshima, Fumihiro Ishida, and Satu Mustjoki. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight jak-stat signaling as therapeutic target. Nature Communications, Apr 2018. URL: https://doi.org/10.1038/s41467-018-03987-2, doi:10.1038/s41467-018-03987-2. This article has 163 citations and is from a highest quality peer-reviewed journal.

  15. (tang2017aggressivenkcellleukemia pages 2-4): Yuan Tang, D. Wang, H. Luo, M. Xiao, H-S Zhou, D. Liu, Shaoping Ling, N. Wang, X-L Hu, Y. Luo, X. Mao, Q. Ao, J. Huang, W. Zhang, L. Sheng, L. Zhu, Z. Shang, L. Gao, P-L Zhang, M. Zhou, K. Zhou, L. Qiu, Q.‐F. Liu, H.-Y. Zhang, J. Li, J. Jin, L. Fu, W-L Zhao, J-P Chen, X. Du, G. Huang, Q-f Wang, J. Zhou, and L. Huang. Aggressive nk-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer Journal, Dec 2017. URL: https://doi.org/10.1038/s41408-017-0021-z, doi:10.1038/s41408-017-0021-z. This article has 72 citations and is from a domain leading peer-reviewed journal.

  16. (NCT03719105 chunk 1): Mitchell Cairo. Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma. New York Medical College. 2019. ClinicalTrials.gov Identifier: NCT03719105

  17. (NCT05863234 chunk 1): Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia. Hiroshima University Hospital. 2023. ClinicalTrials.gov Identifier: NCT05863234